Ivax/Nycomed merger would create contrast media, generic drug firm with $2.5 bil. in sales.
This article was originally published in The Gray Sheet
Executive Summary
IVAX IV BUSINESS TO BENEFIT FROM NYCOMED'S U.S. HOSPITAL TIES as a result of the proposed $6.5 bil. merger of the two firms, the companies say. The deal would enable Ivax' intravenous solutions and products business to "benefit substantially" from the "excellent U.S. hospital relationships" and "international hospital distribution channels" Hafslund Nycomed has established through its market-leading position in contrast imaging agents. Miami-based Ivax and Oslo, Norway-based Hafslund Nycomed announced Oct. 18 a definitive agreement to combine their health care products businesses.